The fact that GLP-1R agonists are sometimes introduced if the patient is intolerant to metformin or metformin is contraindicated, or when patients on metformin are not achieving their HbA1c goals [71] represents essential background information here
Those are Wegovy, Zepbound, or Saxenda
But this study and others linking medication with reduced inflammation continue to underline the importance of inflammation in several major diseases
By enhancing insulin sensitivity and suppressing appetite, Tirzepatide helps reduce caloric intake and improve blood sugar levels, which is particularly beneficial for our patients with type 2 diabetes and obesity
But NICEs recommendation confines reimbursed usage to a very narrow group of patients, much narrower than the label
One catch that trips people up: if you have type 2 diabetes, obstructive sleep apnea, or MASH (metabolic liver disease), you cant use the Bridge at all, even if you clear the BMI thresholds above